Genmab A/S (GMAB) is now covered by Wolfe Research. They set an "outperform" rating and a $32.00 price target on the stock.
Genmab A/S (GMAB) was upgraded by Truist Financial Corporation to "strong-buy".
Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation Debate [Yahoo! Finance]
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches [Yahoo! Finance]